LL344

LL344 is a novel coumarin derivative developed as a dual inhibitor of the efflux transporters P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). Developed through a collaboration between Dongguk University and Ewha Womans University, LL344 is designed to overcome multidrug resistance (MDR) in cancer chemotherapy. By blocking these key ATP-binding cassette (ABC) transporters, LL344 increases the intracellular accumulation and cytotoxicity of chemotherapeutic substrates, such as topotecan and paclitaxel. In preclinical rodent models, oral co-administration of LL344 with topotecan significantly enhances the oral bioavailability of the chemotherapeutic agent and improves its antitumor efficacy in human colon cancer xenografts without causing notable systemic toxicity.

Other names

compound LL344